Combining the monoclonal antibody atezolizumab with a carboplatin-paclitaxel chemotherapy regimen and the biologic antiangiogenic agent bevacizumab led to a significant progression-free survival (PFS) benefit in chemotherapy-naïve patients with non-squamous metastatic non-small-cell lung cancer (mNSCLC), according to the IMpower150* trial presented at ELCC 2018.
Low baseline levels of the biomarker endoglin may signal improved progression-free survival (PFS) and/or overall survival (OS) in chemotherapy-naïve patients with unresectable epithelioid malignant pleural mesothelioma (MPM) who received the triple angiokinase inhibitor nintedanib in addition to a doublet combination regimen comprising pemetrexed and cisplatin, according to results from the LUME Meso* trial presented at ELCC 2018.
Even in the long term, atezolizumab shows significant survival benefit over docetaxel for patients with advanced non-small–cell lung cancer (NSCLC) who have previously been treated, regardless of PD-L1 expression levels or tumour histology, according to the POPLAR* study presented at the 2018 European Lung Cancer Congress (ELCC).
First-generation EGFR tyrosine kinase inhibitor (TKI) therapy is less effective in patients with advanced lung adenocarcinoma who have complex EGFR mutations and primary drug-resistance patterns, according to results of a Chinese study reported at ELCC 2018.
The next-generation TKI* alectinib maintains improvement in lung cancer symptoms for a longer duration than crizotinib, the current standard of care for patients with ALK-positive non-small–cell lung cancer (NSCLC), according to new data from the ALEX** study presented at ELCC 2018.
The first-line use of osimertinib in patients with EGFR mutation–positive advanced non-small-cell lung cancer (NSCLC) is associated with significant improvements in a number of post-progression endpoints compared with current standard of care (SoC), according to new data from the phase III FLAURA study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.